Korro Bio (KRRO) said late Monday the first cohort of participants has been dosed in its phase 1/2 trial of KRRO-121 for the potential treatment of hyperammonemia in patients with urea cycle disorders and patients with hepatic encephalopathy.
The trial is currently enrolling healthy volunteers in Australia and is part of a global phase 1/2 ANCHOR trial program, Korro said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.